The Nori Health App
Primary Purpose
IBD, Crohn Disease, Ulcerative Colitis
Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
The Nori Health app
Sponsored by
About this trial
This is an interventional supportive care trial for IBD focused on measuring Randomized Controlled Trial, Pilot, Qualitative component
Eligibility Criteria
Patients with IBD are eligible for participation if they:
- Are aged >18 years;
- Are able to read and write the Dutch language;
- Are in the possession of a tablet or smartphone with WiFi connection.
Excluded are those with cognitive impairments or who are already familiar with use of the Nori Health app.
Sites / Locations
- RadboudumcRecruiting
- Elisabeth-TweeSteden ZiekenhuisRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Intervention group
Control group
Arm Description
Use of the Nori Health app during the study period, standard care
No use of the Nori Health app during the study period, standard care
Outcomes
Primary Outcome Measures
Patient Activation Measure (PAM)
Measure of patient activation for self-management. Scale from 0 to 100, higher scores mean a higher level of patient activation for self-management (=better outcome).
Secondary Outcome Measures
Patient Activation Measure (PAM)
Measure of patient activation for self-management. Scale from 0 to 100, higher scores mean a higher level of patient activation for self-management (=better outcome).
Inflammatory Bowel Disease (IBD)-control questionnaire
Measure of disease control. Scale from 0 to 16, higher scores mean a higher level of disease control (=better outcome).
EuroQol-5 dimension questionnaire (EQ-5D)
Measure of quality of life. Scale from 0 to 100, higher scores mean a higher quality of life (=better outcome).
Healthcare utilization
Brief questionnaire with 5 close-ended questions on healthcare utilizatio, using a nominal scale (e.g., yes/no).
Full Information
NCT ID
NCT05474742
First Posted
July 8, 2022
Last Updated
July 22, 2022
Sponsor
UMC Utrecht
Collaborators
Elisabeth-TweeSteden Ziekenhuis, Radboud University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT05474742
Brief Title
The Nori Health App
Official Title
The Nori Health App: (Pilot) Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 25, 2022 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
UMC Utrecht
Collaborators
Elisabeth-TweeSteden Ziekenhuis, Radboud University Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
A multicenter, randomized controlled trial with an embedded pilot and qualitative component to investigate the effects of the Nori Health app.
Detailed Description
RATIONALE Inflammatory bowel disease (IBD) is an umbrella term used to describe diseases that involve chronic inflammation of the gastrointestinal tract. Although progress in treatment has been made over the past two decades, IBD continues to profoundly affect patients' quality of life. Since patients with IBD have to deal with their disease's complex and unpredictable nature 24 hours a day, it is important that they have access to self-management support outside the hospital. Nori Health aims to provide this support with an app that consists of an artificial intelligence-driven chatbot and 6-week education program.
OBJECTIVES
The primary objective is to investigate whether use of the Nori Health app improves the level of patient activation for self-management in patients with IBD by comparing an intervention and (waiting-list) control group at 6 weeks after randomization. Secondary objectives are:
To investigate whether there are any differences between the intervention and control group in the level of patient activation for self-management at 12 and 20 weeks after randomization;
To investigate whether there are any differences between the intervention and control group in the level of disease control at 6, 12 and 20 weeks after randomization;
To investigate whether there are any differences between the intervention and control group in quality of life at 6, 12 and 20 weeks after randomization;
To investigate whether there are any differences between the intervention and control group in healthcare utilization at 6, 12 and 20 weeks after randomization;
To investigate intervention fidelity at 6, 12 and 20 weeks after randomization;
To explore the experiences of patients with IBD with use of the Nori Health app and their views on its pros and cons.
STUDY DESIGN A multicenter, randomized controlled trial with an embedded pilot and qualitative component.
STUDY POPULATION
Patients with IBD are eligible for participation if they:
Are aged >18 years;
Are able to read and write the Dutch language;
Are in the possession of a tablet or smartphone with WiFi connection.
Excluded are those with cognitive impairments or who are already familiar with use of the Nori Health app.
STUDY INTERVENTION Participants are randomized in a 1:1 ratio to the intervention or control group. Participants in the intervention group receive access to the Nori Health app for a 6-month period directly after randomization. They are free to use the Nori Health app whenever and as often as they want. Participants in the control group receive no intervention. Standard IBD care continues unchanged. After study completion, participants in the control group also receive access to the Nori Health app for a 6-month period.
STUDY PARAMETERS The level of patient activation for self-management is assessed using the patient activation measure. The IBD control questionnaire and EQ-5D are used to assess respectively the level of disease control and quality of life. Healthcare utilization is assessed with 5 close-ended questions. System data is used to assess intervention fidelity. Experiences of patients with IBD with use of the Nori Health app and their views on its pros and cons are explored by performing individual, semi-structured, telephonic interviews.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
IBD, Crohn Disease, Ulcerative Colitis
Keywords
Randomized Controlled Trial, Pilot, Qualitative component
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
168 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention group
Arm Type
Experimental
Arm Description
Use of the Nori Health app during the study period, standard care
Arm Title
Control group
Arm Type
No Intervention
Arm Description
No use of the Nori Health app during the study period, standard care
Intervention Type
Other
Intervention Name(s)
The Nori Health app
Intervention Description
The Nori Health app consist of a chatbot that instantly answers questions about topics relevant to patients with IBD and 6-week education program. The chatbot is driven by artificial intelligence and armed with state of the art scientific literature to offer to the right information to the right person at the right time. The education program is offered during the first six weeks of use. The Nori Health app then actively offers information on four fixed topics and two topics to a participant's choosing (i.e. low energy, pain, stress, mental health, hydration, exercising). It is expected from participants that they respond to this by having approximately five chat conversations of five minutes per week. Participants in the intervention group receive access to the Nori Health app for a 6-month period directly after randomization. They are free to use the Nori Health app whenever and as often as they want. Participants in the control group receive no intervention.
Primary Outcome Measure Information:
Title
Patient Activation Measure (PAM)
Description
Measure of patient activation for self-management. Scale from 0 to 100, higher scores mean a higher level of patient activation for self-management (=better outcome).
Time Frame
6 weeks follow-up
Secondary Outcome Measure Information:
Title
Patient Activation Measure (PAM)
Description
Measure of patient activation for self-management. Scale from 0 to 100, higher scores mean a higher level of patient activation for self-management (=better outcome).
Time Frame
12 and 20 weeks follow-up
Title
Inflammatory Bowel Disease (IBD)-control questionnaire
Description
Measure of disease control. Scale from 0 to 16, higher scores mean a higher level of disease control (=better outcome).
Time Frame
6, 12 and 20 weeks follow-up
Title
EuroQol-5 dimension questionnaire (EQ-5D)
Description
Measure of quality of life. Scale from 0 to 100, higher scores mean a higher quality of life (=better outcome).
Time Frame
6, 12 and 20 weeks follow-up
Title
Healthcare utilization
Description
Brief questionnaire with 5 close-ended questions on healthcare utilizatio, using a nominal scale (e.g., yes/no).
Time Frame
6, 12 and 20 weeks follow-up
Other Pre-specified Outcome Measures:
Title
Interviews
Description
Experiences of patients with IBD with use of the Nori Health app and their views on its pros and cons.
Time Frame
6-20 weeks follow-up
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Patients with IBD are eligible for participation if they:
Are aged >18 years;
Are able to read and write the Dutch language;
Are in the possession of a tablet or smartphone with WiFi connection.
Excluded are those with cognitive impairments or who are already familiar with use of the Nori Health app.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elke Mathijssen, PhD
Phone
0031627247920
Email
e.g.e.mathijssen-2@umcutrecht.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Jaap Trappenburg, PhD
Email
jtrappen@umcutrecht.nl
Facility Information:
Facility Name
Radboudumc
City
Nijmegen
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marjolijn Duijvestein
Facility Name
Elisabeth-TweeSteden Ziekenhuis
City
Tilburg
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dominique Bierens-Peters
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
The Nori Health App
We'll reach out to this number within 24 hrs